Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.42 |
| ▸ | MGLL | Q99685 | 3/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9322926 | 1.00 | GBA1 (0.44) | GBA1PTGS1PTGS2MGLLFAAH | |
| SCHEMBL10721232 | 1.00 | GBA1 (0.44) | GBA1PTGS1PTGS2MGLLFAAH | |
| SCHEMBL25752208 | 1.00 | GBA1 (0.44) | GBA1PTGS1PTGS2MGLLFAAH | |
| SCHEMBL31728677 | 1.00 | GBA1 (0.44) | GBA1PTGS1PTGS2MGLLFAAH | |
| SCHEMBL6561436 | 1.00 | GBA1 (0.44) | GBA1PTGS1PTGS2MGLLFAAH | |
| SCHEMBL31729293 | 1.00 | GBA1 (0.44) | GBA1PTGS1PTGS2MGLLFAAH | |
| SCHEMBL10721244 | 1.00 | GBA1 (0.44) | GBA1PTGS1PTGS2MGLLFAAH | |
| SCHEMBL4421020 | 0.98 | GBA1 (0.41) | GBA1PTGS1PTGS2MGLLFAAH | |
| SCHEMBL21808765 | 0.93 | ALOX5 (0.41) | GBA1PTGS1PTGS2MGLLFAAH | |
| SCHEMBL750176 | 0.92 | MEN1 (0.41) | GBA1ALOX5S1PR1ALDH1A1CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | GBA1 503/4885PTGS1 4765/4885PTGS2 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.